Medical therapies for hepatocellular carcinoma: a critical view of the evidence.
about
Epigenetic Activation of Wnt/β-Catenin Signaling in NAFLD-Associated HepatocarcinogenesisThe Role of Autophagy in Hepatocellular CarcinomaTargeting the insulin-like growth factor pathway in hepatocellular carcinomaA Recent Advance in Image-Guided Locoregional Therapy for Hepatocellular CarcinomaHER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologistsApplying NGS Data to Find Evolutionary Network Biomarkers from the Early and Late Stages of Hepatocellular Carcinoma.Pretreatment platelet count early predicts extrahepatic metastasis of human hepatoma.MiR-375 and Doxorubicin Co-delivered by Liposomes for Combination Therapy of Hepatocellular Carcinoma.Effects of miR-193a and sorafenib on hepatocellular carcinoma cells.GALNT14 genotype, α-fetoprotein and therapeutic side effects predict post-chemotherapy survival in patients with advanced hepatocellular carcinoma.Immunotherapeutic approaches for hepatocellular carcinomaAdvanced-stage hepatocellular carcinoma with portal vein thrombosis: conventional versus drug-eluting beads transcatheter arterial chemoembolization.Identification of four prognostic LncRNAs for survival prediction of patients with hepatocellular carcinoma.The GH-IGF-SST system in hepatocellular carcinoma: biological and molecular pathogenetic mechanisms and therapeutic targets.CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinomaRocaglamide overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells by attenuating the inhibition of caspase-8 through cellular FLICE-like-inhibitory protein downregulation.Role of the staphylococcal nuclease and tudor domain containing 1 in oncogenesis (review).An atypical age-specific pattern of hepatocellular carcinoma in Peru: a threat for Andean populations.Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations.Minimally invasive local therapies for liver cancerIncreased ARPP-19 expression is associated with hepatocellular carcinomaStereotactic body radiation therapy for hepatocellular carcinoma: prognostic factors of local control, overall survival, and toxicityLocally ablative therapies for primary and metastatic liver cancer.Predictors of mortality in patients with hepatocellular carcinoma undergoing transarterial chemoembolization.CCAAT/enhancer binding protein α predicts poorer prognosis and prevents energy starvation-induced cell death in hepatocellular carcinomaCorosolic Acid Inhibits Hepatocellular Carcinoma Cell Migration by Targeting the VEGFR2/Src/FAK Pathway.Network-Based Analysis of Nutraceuticals in Human Hepatocellular Carcinomas Reveals Mechanisms of Chemopreventive ActionCell death and cell death responses in liver disease: mechanisms and clinical relevanceAstaxanthin Inhibits Proliferation and Induces Apoptosis of Human Hepatocellular Carcinoma Cells via Inhibition of Nf-Κb P65 and Wnt/Β-Catenin in Vitro.CXCR7 stimulates MAPK signaling to regulate hepatocellular carcinoma progression.Tumor Suppressive Function of p21-activated Kinase 6 in Hepatocellular CarcinomaOnco-proteogenomics identifies urinary S100A9 and GRN as potential combinatorial biomarkers for early diagnosis of hepatocellular carcinoma.A Gene Expression Signature Associated with Overall Survival in Patients with Hepatocellular Carcinoma Suggests a New Treatment Strategy.HBx-related long non-coding RNA DBH-AS1 promotes cell proliferation and survival by activating MAPK signaling in hepatocellular carcinoma.TLR4 Signaling via NANOG Cooperates With STAT3 to Activate Twist1 and Promote Formation of Tumor-Initiating Stem-Like Cells in Livers of Mice.Aspartate β-hydroxylase modulates cellular senescence through glycogen synthase kinase 3β in hepatocellular carcinoma.Iron-Oxide-Based Nanovector for Tumor Targeted siRNA Delivery in an Orthotopic Hepatocellular Carcinoma Xenograft Mouse ModelSorafenib in advanced hepatocellular carcinoma: current status and future perspectives.An alternatively spliced variant of CXCR3 mediates the metastasis of CD133+ liver cancer cells induced by CXCL9Identification and Validation of HCC-specific Gene Transcriptional Signature for Tumor Antigen Discovery.
P2860
Q26739018-06CE8D16-05A2-4C62-A2DC-A8D4386D1994Q26777419-09FD0982-09DB-423B-9399-E4382F8FDA98Q27006846-C6B48010-9CF7-413A-B52D-D93CE8E55BF2Q28067517-FDAAACFF-2182-481D-B3DF-286F97519CBAQ28078111-3A775B0B-635F-4FF0-8741-3C6AF9616BACQ30993390-6C283DFE-F135-4F18-B021-F8745561BB75Q33420986-9C0A32C8-3FC9-4A9B-B85A-65378A0EF046Q33635350-207B8E8C-5694-467D-9C3F-F583CCBF568DQ33644158-BC59D683-E8CB-40C9-AEBB-B2DF9FD57B90Q33733830-02DCE186-0E4E-42A2-A801-2AF91316AC46Q33779723-57BBF4E5-9D17-46CC-9A11-C2193B051ABDQ33797067-C744D8C1-E292-42C8-A0AA-CC5FE57627A2Q33919936-D4237C21-B47B-4176-A7BF-3C7E89CD0D74Q34182483-1061B741-566C-484E-B28B-3B1CCD137418Q34342934-DFF2444F-F2B1-44D3-8DF9-51A956966CECQ34540808-69A9FF7A-2DA1-4031-AD7A-3976AF918776Q34775841-964D51A0-149C-4456-9EF0-B9AD7B6C62E7Q34807998-ACA33210-6C53-4983-BF3E-34A0587A7D70Q34827556-7A9C413B-56F4-42C7-94E2-FCDF298FF73EQ34974386-9AABEAB0-E47B-4CCE-8CB6-BBBD88BE4516Q35016406-CAFFBD39-EC31-4204-84A4-12AB934CB469Q35023155-1126F5FB-52AF-4185-8F33-C029EA682BB6Q35152457-7873FC21-7C6C-457A-A2CE-E3A74A44FD36Q35178251-10D1D7AB-4A78-4853-AAC8-E571A1600A3CQ35194416-999E5B7C-EA21-41F6-BB39-9A1F6E9F669BQ35610912-8AA15373-769A-44A8-A46F-9A351F82AC7CQ35861710-77559BB2-7E11-4933-A1D1-FEDBF2EB9718Q35938040-4B4CE2A5-C0D2-4E5D-AB3F-29D4D2B427B2Q36226728-1D78D289-4C0C-4C04-BE60-99CCC4393482Q36291113-B2060CD1-F3B2-4C91-9829-53C179E5CD92Q36301347-59868C78-1319-465E-9EE0-A2CEACD286BCQ36347633-29625BFE-E625-42B8-90EB-D26EFA06A29AQ36502944-8962FC8C-6830-440D-8093-01FCB71A6EB6Q36545292-09C4641D-CBBA-442F-A536-8DFE919192F0Q36614492-FBB99298-BB8E-4BA5-ADBB-900B06CBA2B5Q36723189-5E344275-E994-4B3D-A85C-0E6B43D551DFQ36792563-C7F9EFE9-4D6A-4522-B8C1-224DD51E3468Q37031712-79B4AAF7-7E11-48AF-A450-9C6F6BE6E340Q37046628-C6FCC4FB-25E2-4E60-AD16-66202521F72EQ37076019-3970FEE7-FE90-4BCF-BC1F-FEBE9776BFB5
P2860
Medical therapies for hepatocellular carcinoma: a critical view of the evidence.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Medical therapies for hepatocellular carcinoma: a critical view of the evidence.
@en
type
label
Medical therapies for hepatocellular carcinoma: a critical view of the evidence.
@en
prefLabel
Medical therapies for hepatocellular carcinoma: a critical view of the evidence.
@en
P2860
P50
P1476
Medical therapies for hepatocellular carcinoma: a critical view of the evidence.
@en
P2860
P2888
P356
10.1038/NRGASTRO.2012.199
P407
P577
2012-11-13T00:00:00Z